Literature DB >> 18178086

Discovery of potent LPA2 (EDG4) antagonists as potential anticancer agents.

Hilary P Beck1, Todd Kohn, Steven Rubenstein, Christine Hedberg, Ralf Schwandner, Kerstin Hasslinger, Kang Dai, Cong Li, Lingming Liang, Holger Wesche, Brendon Frank, Songhzu An, Dineli Wickramasinghe, Juan Jaen, Julio Medina, Randall Hungate, Wang Shen.   

Abstract

The LPA(2) protein is overexpressed in many tumor cells. We report the optimization of a series of LPA(2) antagonists using calcium mobilization assay (aequorin assay) that led to the discovery of the first reported inhibitors selective for LPA(2). Key compounds were evaluated in vitro for inhibition of LPA(2) mediated Erk activation and proliferation of HCT-116 cells. These compounds could be used to evaluate the benefits of LPA(2) inhibition both in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18178086     DOI: 10.1016/j.bmcl.2007.12.024

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  13 in total

1.  Autotaxin and LPA1 and LPA5 receptors exert disparate functions in tumor cells versus the host tissue microenvironment in melanoma invasion and metastasis.

Authors:  Sue-Chin Lee; Yuko Fujiwara; Jianxiong Liu; Junming Yue; Yoshibumi Shimizu; Derek D Norman; Yaohong Wang; Ryoko Tsukahara; Erzsebet Szabo; Renukadevi Patil; Souvik Banerjee; Duane D Miller; Louisa Balazs; Manik C Ghosh; Christopher M Waters; Tamas Oravecz; Gabor J Tigyi
Journal:  Mol Cancer Res       Date:  2014-08-26       Impact factor: 5.852

2.  Uncovering unique roles of LPA receptors in the tumor microenvironment.

Authors:  Sue-Chin Lee; Yuko Fujiwara; Gabor J Tigyi
Journal:  Receptors Clin Investig       Date:  2015

3.  The autotaxin-LPA2 GPCR axis is modulated by γ-irradiation and facilitates DNA damage repair.

Authors:  Andrea Balogh; Yoshibumi Shimizu; Sue Chin Lee; Derek D Norman; Ruchika Gangwar; Mitul Bavaria; ChangSuk Moon; Pradeep Shukla; Radakrishna Rao; Ramesh Ray; Anjaparavanda P Naren; Souvik Banerjee; Souvik Banerje; Duane D Miller; Louisa Balazs; Louis Pelus; Gabor Tigyi
Journal:  Cell Signal       Date:  2015-05-28       Impact factor: 4.315

Review 4.  Aiming drug discovery at lysophosphatidic acid targets.

Authors:  Gabor Tigyi
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

Review 5.  The biology of ovarian cancer: new opportunities for translation.

Authors:  Robert C Bast; Bryan Hennessy; Gordon B Mills
Journal:  Nat Rev Cancer       Date:  2009-06       Impact factor: 60.716

Review 6.  LPA receptor signaling: pharmacology, physiology, and pathophysiology.

Authors:  Yun C Yung; Nicole C Stoddard; Jerold Chun
Journal:  J Lipid Res       Date:  2014-03-18       Impact factor: 5.922

7.  Special Agents Hunting Down Women Silent Killer: The Emerging Role of the p38α Kinase.

Authors:  Valentina Grossi; Cristiano Simone
Journal:  J Oncol       Date:  2012-03-11       Impact factor: 4.375

8.  Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways.

Authors:  Donavon Hiss
Journal:  J Oncol       Date:  2012-02-06       Impact factor: 4.375

9.  Glucagon-like Peptide-1 Secretion Is Inhibited by Lysophosphatidic Acid.

Authors:  Maria F Fernandes; Michelle V Tomczewski; Robin E Duncan
Journal:  Int J Mol Sci       Date:  2022-04-09       Impact factor: 6.208

Review 10.  Promising pharmacological directions in the world of lysophosphatidic Acid signaling.

Authors:  Nicole C Stoddard; Jerold Chun
Journal:  Biomol Ther (Seoul)       Date:  2015-01-01       Impact factor: 4.634

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.